Publications by authors named "Andrew D Siderowf"

Claim this Profile
C
Current Status of α-Synuclein Biomarkers and the Need for α-Synuclein PET Tracers.
Sara E Berman, Andrew D Siderowf

Cells· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot Study of [C]HY-2-15: A Mixed Alpha-Synuclein and Tau PET Radiotracer.
Chia-Ju Hsieh, Dinahlee Saturnino Guarino, Anthony J Young, Andrew D Siderowf, Ilya Nasrallah

Cells· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease.
David G Coughlin, Ben Shifflett, Carly M Farris, Yihua Ma, Douglas Galasko, Andrew D Siderowf

Neurology· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Dementia Risk in Parkinson Disease.
Julia Gallagher, Caroline Gochanour, Chelsea Caspell-Garcia, Roseanne D Dobkin, Dag Aarsland, Andrew D Siderowf

Neurology· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of ATN Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease.
Katheryn A Q Cousins, David J Irwin, Thomas F Tropea, Emma Rhodes, Jeffrey Phillips, Andrew D Siderowf

Neurology· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trial of Cinpanemab in Early Parkinson's Disease.
Anthony E Lang, Andrew D Siderowf, Eric A Macklin, Werner Poewe, David J Brooks

N Engl J Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The importance of preclinical diagnostics in Parkinson disease.
Sneha Mantri, James F Morley, Andrew D Siderowf

Parkinsonism Relat Disord· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
David Coughlin, Sharon X Xie, Mendy Liang, Andrew Williams, Claire Peterson, Andrew D Siderowf

Ann Neurol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.
Rizwan S Akhtar, Sharon X Xie, Yin J Chen, Jacqueline Rick, Rachel G Gross, Andrew D Siderowf

PLoS One· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia.
Rizwan S Akhtar, Sharon X Xie, Laura Brennan, Michael J Pontecorvo, Howard I Hurtig, Andrew D Siderowf

Mov Disord Clin Pract· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research on the premotor symptoms of Parkinson's disease: clinical and etiological implications.
Honglei Chen, Edward A Burton, G Webster Ross, Xuemei Huang, Rodolfo Savica, Andrew D Siderowf

Environ Health Perspect· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

JAMA Neurol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Costs of Parkinson's disease in a privately insured population.
Scott J Johnson, Anna Kaltenboeck, Melissa Diener, Howard G Birnbaum, Elizabeth Grubb, Andrew D Siderowf

Pharmacoeconomics· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations.
Lama M Chahine, Judy Qiang, Emily Ashbridge, James Minger, Dora Yearout, Andrew D Siderowf

JAMA Neurol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An economic model of Parkinson's disease: implications for slowing progression in the United States.
Scott J Johnson, Melissa D Diener, Anna Kaltenboeck, Howard G Birnbaum, Andrew D Siderowf

Mov Disord· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease.
Katrina L Paumier, Andrew D Siderowf, Peggy Auinger, David Oakes, Lalitha Madhavan

Mov Disord· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphorylated α-synuclein in Parkinson's disease.
Yu Wang, Min Shi, Kathryn A Chung, Cyrus P Zabetian, James B Leverenz, Andrew D Siderowf

Sci Transl Med· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurodegeneration across stages of cognitive decline in Parkinson disease.
Daniel Weintraub, Jimit Doshi, Deepthi Koka, Christos Davatzikos, Andrew D Siderowf

Arch Neurol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease.
James F Morley, Daniel Weintraub, Eugenia Mamikonyan, Paul J Moberg, Andrew D Siderowf

Mov Disord· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impulse control disorders in Parkinson disease: a multicenter case--control study.
Valerie Voon, Mandy Sohr, Anthony E Lang, Marc N Potenza, Andrew D Siderowf

Ann Neurol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: validity and variability.
Kimberly Papay, Eugenia Mamikonyan, Andrew D Siderowf, John E Duda, Kelly E Lyons

Parkinsonism Relat Disord· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study.
Elise Caccappolo, Roy N Alcalay, Helen Mejia-Santana, Ming-X Tang, Brian Rakitin, Andrew D Siderowf

J Int Neuropsychol Soc· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study.
Daniel Weintraub, Mandy Sohr, Marc N Potenza, Andrew D Siderowf, Mark Stacy

Ann Neurol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased ventral striatal activity with impulse control disorders in Parkinson's disease.
Hengyi Rao, Eugenia Mamikonyan, John A Detre, Andrew D Siderowf, Matthew B Stern

Mov Disord· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study.
Karen S Marder, Ming X Tang, Helen Mejia-Santana, Llency Rosado, Elan D Louis, Andrew D Siderowf

Arch Neurol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis